 - Patient may have primary or secondary hepatic malignancies with a FLRTLV 30 or a FLRBW ratio of 0.5 for patients with normal liver function defined as normal transaminases, normal bilirubin, normal factor V, and normal PTINR. In case of injury due to chemotherapy, known high grade steatosis, or cholestasis 50 mmolL, patient may be enrolled into the trial if FLRTLV is 40 or FLRBW ratio 0.8. 